NY-CALVIN-KLEIN-INC
3.8.2020 13:02:08 CEST | Business Wire | Press release
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today revealed the worldwide global advertising campaign for ETERNITY Calvin Klein with the return of maternal health activist and model Christy Turlington Burns, alongside her husband, director, writer, producer and actor Edward Burns, as the faces of the ETERNITY campaign.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005090/en/
ETERNITY Calvin Klein advertising has artfully and unforgettably captured the promise of romance, intimacy, and commitment. Together, Turlington Burns who starred in the first ETERNITY advertising campaign when it debuted in 1988, and Burns who has appeared next to his wife in the 2014 and 2016 campaigns, bring to life the essence of the ETERNITY love story with their timeless relationship.
Today, the ETERNITY story continues with the iconic couple in a new television and print campaign that portrays an enduring love rooted in sensuality, authenticity, spontaneity, and supports the launch of the new ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein.
“After shooting the first ETERNITY Calvin Klein campaign ever over 30 years ago, it’s a pleasure to be working with Calvin Klein again and to continue to be a part of the history of such an iconic fragrance,” said Turlington Burns + Burns jointly. “We are honored to be part of this new campaign celebrating our relationship with ETERNITY Calvin Klein.”
The television campaign is captured by filmmaker and photographer Matt Lambert and is a combination of traditional black and white in addition to color shots. This juxtaposition conveys their committed past with the strength of their present relationship. The campaign, a compilation of joyful moments by the ocean, is an homage to their love story and is set to a reimagined cover of the iconic love song ‘Unchained Melody’ by Lykke Li.
Lachlan Bailey photographed the iconic couple in a classic black and white still campaign visual on the beach. Turlington Burns' hair is effortlessly being swept back by the ocean breeze while Burns adoringly pulls her toward him. The image is just one of many memories in time for the couple, a stolen moment in their endless love story.
“We are thrilled to welcome back such an iconic couple to celebrate the next chapter of ETERNITY Calvin Klein which continues its legacy as one of the most beloved fragrances for both men and women,” said Simona Cattaneo, President of Luxury Brands at Coty. “With this new campaign ETERNITY continues to inspire timeless love; its romantic values are undimmed by the passing of time and still resonate with consumers today.”
In addition to supporting ETERNITY Calvin Klein Signature, the campaign also supports the new line extension ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein through the still campaign visual also shot by Bailey. The hero image is an injection of happiness and bursts of freshness; Turlington Burns and Burns are captured playfully frolicking in the ocean, holding each other closely as the waves splash around them.
Evoking the free-spirited nature of the ocean and the joy of strolling through a beautiful sensual garden, the line extension inspires spontaneity while celebrating the spirit of eternal love. The enduring legacy of the ETERNITY Calvin Klein Signature is playfully reimagined for modern lovers with fresh green ingredients in ETERNITY Cologne for him Calvin Klein by perfumers Julie Massé, Ralf Schwieger and Véronique Nyberg of Mane and romantic watery florals in ETERNITY Eau Fresh for her Calvin Klein by perfumers Olivier Gillotin and Sonia Constant of Givaudan.
ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein are available for sale globally starting today on a rolling basis.
About Calvin Klein, Inc.:
CALVIN KLEIN is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.
Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of CALVIN KLEIN brand products exceeded $9 billion in 2019 and were distributed in over 110 countries. Calvin Klein employs over 11,500 associates globally. We were acquired by PVH Corp. in 2003.
About COTY Inc.
Coty is one of the world’s largest beauty companies with approximately $9 billion in revenue, with a purpose to celebrate and liberate the diversity of consumers’ beauty. Its strong entrepreneurial heritage has created an iconic portfolio of leading beauty brands. Coty is the global leader in fragrance, a strong number two in professional salon hair color & styling, and number three in color cosmetics. Coty operates three divisions – Coty Consumer Beauty, which is focused on color cosmetics, retail hair coloring and styling products, body care and mass fragrances sold primarily in the mass retail channels with brands such as Bourjois, Max Factor, Rimmel, Wella, Adidas and Guess; Coty Luxury, which is focused on prestige fragrances and skincare with brands such as Gucci, Hugo Boss, Calvin Klein, Chloe, Bottega Veneta and Alexander McQueen; and Coty Professional Beauty, which is focused on servicing salon owners and professionals in both hair and nail, with brands such as Wella Professionals, System Professional, OPI and ghd. Coty has approximately 20,000 colleagues globally and its products are sold in over 130 countries. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com .
ADVERTISING CREDITS:
Creative Direction: Calvin Klein and Mazarine
Campaign Videos: Matt Lambert
Advertising Campaign images: Lachlan Bailey
EDITORIAL CREDIT:
ETERNITY For Women Eau de Parfum CALVIN KLEIN
ETERNITY For Men Eau de toilette CALVIN KLEIN
ETERNITY Eau Fresh for her CALVIN KLEIN
ETERNITY Cologne for him CALVIN KLEIN
TVC: https://youtu.be/NN9Q2pKiDKE
SOCIAL MEDIA: #cketernity
BRAND HANDLE: @calvinklein
View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom